In addition, strong nuclear immunoreactivity of HNF-1B was observed in 16 of 21 (76.1%) clear cell carcinomas of the kidney, 10 of 14 (71.4%) ovarian clear cell carcinomas, 6 of 24 (25%) lung adenocarcinomas, and 4 of 15 (26.7%) prostate adenocarcinomas. This evidence concerns the gene HNF1B and lung adenocarcinoma.